Published in Chemotherapy on January 01, 1985
Coelioscopic cholecystectomy. Preliminary report of 36 cases. Ann Surg (1990) 6.83
[Cholecystectomy by coelioscopy]. Presse Med (1989) 2.19
Fibroid-related menorrhagia: treatment with superselective embolization of the uterine arteries and midterm follow-up. Radiology (2000) 2.09
In vitro activities of the new ketolide antibiotics HMR 3004 and HMR 3647 against Streptococcus pneumoniae in Germany. Antimicrob Agents Chemother (1998) 1.67
[Diffusion of ofloxacin in human lung tissue]. Infection (1986) 1.65
Laparoscopic cholecystectomy: historic perspective and personal experience. Surg Laparosc Endosc (1991) 1.64
[Appendiceal mucoceles, pseudomyxoma peritonei and appendiceal mucinous neoplasms: update on the contribution of imaging to choice of surgical approach]. J Chir (Paris) (2009) 1.58
Antibacterial activity of roxithromycin: a laboratory evaluation. J Antibiot (Tokyo) (1986) 1.52
In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors. Antimicrob Agents Chemother (2000) 1.43
Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob Agents Chemother (1998) 1.42
In vitro activities of 14 antibiotics against 100 human isolates of Yersinia pestis from a southern African plague focus. Antimicrob Agents Chemother (1996) 1.42
Classification of oral cephalosporins. A matter for debate. Int J Antimicrob Agents (2001) 1.38
Distribution of beta-lactamases and phenotype analysis in clinical strains of Acinetobacter calcoaceticus. J Antimicrob Chemother (1988) 1.33
Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e. V. Infection (1994) 1.31
The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection. Antimicrob Agents Chemother (1997) 1.30
In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother (2003) 1.25
Clinical and bacteriologic epidemiology of extended-spectrum beta-lactamase-producing strains of Klebsiella pneumoniae in a medical intensive care unit. Clin Infect Dis (1998) 1.25
In vitro activities of the ketolides telithromycin (HMR 3647) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. Antimicrob Agents Chemother (2000) 1.20
Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother (2000) 1.15
In vitro activities of telithromycin (HMR 3647) against Rickettsia rickettsii, Rickettsia conorii, Rickettsia africae, Rickettsia typhi, Rickettsia prowazekii, Coxiella burnetii, Bartonella henselae, Bartonella quintana, Bartonella bacilliformis, and Ehrlichia chaffeensis. Antimicrob Agents Chemother (2000) 1.13
Enzymatic resistance to beta-lactams and aminoglycosides in Acinetobacter calcoaceticus. J Antimicrob Chemother (1987) 1.11
A beta-lactamase-overproducing strain of Alcaligenes denitrificans subsp. xylosoxydans isolated from a case of meningitis. J Antimicrob Chemother (1992) 1.08
Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany. Microb Drug Resist (2001) 1.08
[Present status of nitroxoline]. Pathol Biol (Paris) (1987) 1.07
Penetration of ciprofloxacin into bronchial secretions. Eur J Clin Microbiol (1986) 1.07
Viridans group streptococci: a reservoir of resistant bacteria in oral cavities. Clin Microbiol Infect (2002) 1.07
Trometamol-fosfomycin (Monuril) bioavailability and food-drug interaction. Eur Urol (1987) 1.06
Bactericidal in-vitro activity of beta-lactams and beta-lactamase inhibitors, alone or associated, against clinical strains of Acinetobacter baumannii: effect of combination with aminoglycosides. J Antimicrob Chemother (1995) 1.05
Penetration of ampicillin into human bronchial secretions. Infection (1979) 1.04
Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. J Antimicrob Chemother (2000) 1.04
Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. Antimicrob Agents Chemother (1992) 1.04
Prosthetic valve endocarditis due to Thermomyces lanuginosus Tsiklinsky--first case report. J Med Vet Mycol (1991) 1.04
Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparison. J Antimicrob Chemother (1985) 1.02
Identification of a carbenicillin-hydrolyzing beta-lactamase in Alcaligenes denitrificans subsp. xylosoxydans. Antimicrob Agents Chemother (1995) 1.01
In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs. Antimicrob Agents Chemother (1993) 1.01
[Sensitivity of Pseudomonas aeruginosa and Klebsiella spp. to ceftazidime. Current status in France]. Presse Med (1988) 1.00
Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. J Antimicrob Chemother (1991) 0.99
Pharmacokinetics of cefotiam administered intravenously and intramuscularly to healthy adults. Antimicrob Agents Chemother (1984) 0.98
Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex. Antimicrob Agents Chemother (1994) 0.98
Relative potential for selection of fluoroquinolone-resistant Streptococcus pneumoniae strains by levofloxacin: comparison with ciprofloxacin, sparfloxacin and ofloxacin. J Antimicrob Chemother (1999) 0.98
In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 0.97
[RU 28965, a new semi-synthetic macrolide. Bioavailability and pharmacokinetic profile after oral administration]. Pathol Biol (Paris) (1985) 0.97
Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes. Antimicrob Agents Chemother (2001) 0.95
Diffusion of ofloxacin into human lung tissue. Drugs (1987) 0.95
[Arterial embolization: a new treatment of menorrhagia in uterine fibroma]. Presse Med (1995) 0.95
[Complications of celioscopic cholecystectomy in 2006 patients]. Ann Chir (1994) 0.95
Epidemiological survey of a major outbreak of nosocomial legionellosis. Int J Epidemiol (1987) 0.94
[Epidemic of trichinosis of Egyptian origin. Apropos of 6 cases observed in Paris]. Ann Med Interne (Paris) (1976) 0.94
[Epidemiology of Acinetobacter calcoaceticus]. Nouv Presse Med (1980) 0.93
In-vitro activity of sparfloxacin, pefloxacin, ciprofloxacin and temafloxacin against clinical isolates of Acinetobacter spp. J Antimicrob Chemother (1992) 0.93
[Pharmacokinetic study of antibiotics in human respiratory tract (author's transl)]. Nouv Presse Med (1978) 0.92
Effect of proinflammatory cytokines on the interplay between roxithromycin, HMR 3647, or HMR 3004 and human polymorphonuclear neutrophils. Antimicrob Agents Chemother (2000) 0.90
Mechanism underlying levofloxacin uptake by human polymorphonuclear neutrophils. Antimicrob Agents Chemother (1999) 0.90
Place of emergency arterial embolisation in obstetric haemorrhage about 16 personal cases. Eur J Obstet Gynecol Reprod Biol (1996) 0.90
Pharmacokinetic study of beta-lactam antibiotics in bronchial secretions. Scand J Infect Dis Suppl (1978) 0.89
Molecular analysis of Mycobacterium avium isolates by using pulsed-field gel electrophoresis and PCR. J Clin Microbiol (1999) 0.89
In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia. J Antimicrob Chemother (2000) 0.89
Similar slow down in running speed progression in species under human pressure. J Evol Biol (2012) 0.88
Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex. J Antimicrob Chemother (2000) 0.88
Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother (1996) 0.88
In-vitro antibacterial activity of cefepime: a multicentre study. J Antimicrob Chemother (1993) 0.87
Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother (1995) 0.87
In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study. J Antimicrob Chemother (1999) 0.87
[Pharmacokinetics of ofloxacin in the elderly (65-85 years) with normal renal function after a single oral dose of 200 mg]. Pathol Biol (Paris) (1986) 0.87
Antibiotic susceptibilities of Parachlamydia acanthamoeba in amoebae. Antimicrob Agents Chemother (2002) 0.86
Susceptibility of 100 strains of Stenotrophomonas maltophilia to three beta-lactams and five beta-lactam-beta-lactamase inhibitor combinations. J Antimicrob Chemother (1997) 0.85
The suppository form of antibiotic administration: pharmacokinetics and clinical application. J Antimicrob Chemother (1999) 0.85
Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection. J Antimicrob Chemother (1991) 0.85
[Sensitivity of obligate anaerobes to ofloxacin, pefloxacin, enoxacin and norfloxacin]. Pathol Biol (Paris) (1985) 0.84
Effect of pH on the susceptibility of Helicobacter pylori to the ketolide telithromycin (HMR 3647) and clarithromycin. J Antimicrob Chemother (2001) 0.84
[Umbilical metastasis of an endometrial adenocarcinoma: "Sister (Mary) Joseph's nodule". Review of the literature]. J Gynecol Obstet Biol Reprod (Paris) (1996) 0.84
[Appendectomies by celioscopy. Results in 78 patients]. Ann Chir (1992) 0.84
[Comparative activity in vitro of ceftizoxime, ceftazidime and imipenem against Acinetobacter calcoaceticus]. Pathol Biol (Paris) (1986) 0.83
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). Antimicrob Agents Chemother (1998) 0.83
In-vitro susceptibility of Rhodococcus equi to 27 antibiotics. J Antimicrob Chemother (1991) 0.83
Nosocomial endocarditis in the intensive care unit: an analysis of 22 cases. Crit Care Med (2000) 0.83
Initial chemoimmunotherapy in inflammatory carcinoma of the breast. Cancer (1982) 0.83
[A case of Pseudomonas mendocina endocarditis]. Med Mal Infect (2010) 0.82
[Diffusion of piperacillin into bronchial secretions]. Pathol Biol (Paris) (1986) 0.82
A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother (1999) 0.82
[Cholecystectomy under celioscopy]. Ann Chir (1990) 0.82
[Pharmacokinetics of amikacin in bronchial secretions]. Nouv Presse Med (1979) 0.81
Pharmacokinetic study of cefmenoxime (SCE 1365-CMX) in healthy adults. Am J Med (1984) 0.81
Coelioscopic cholecystectomy: experience with 2006 cases. World J Surg (1995) 0.81
[The influence of rifampicin upon the metabolism of isoniazid (author's transl)]. Nouv Presse Med (1978) 0.80
[Bronchial diffusion of new anti-pseudomonal beta-lactams. Clinical significance]. Pathol Biol (Paris) (1984) 0.80
In-vitro antimicrobial activity of HMR 3004 (RU 64004) against erythromycin A-sensitive and -resistant Corynebacterium spp. isolated from clinical specimens. J Antimicrob Chemother (1998) 0.80
The bactericidal activities of HMR 3004, HMR 3647 and erythromycin against gram-positive bacilli and development of resistance. J Antimicrob Chemother (1999) 0.79
Preparation of stock solutions of macrolide and ketolide compounds for antimicrobial susceptibility tests. Clin Microbiol Infect (2004) 0.79
[Ovarian carcinomas. Intraperitoneal chemotherapy by needle]. Presse Med (1991) 0.79
[Mixed pneumopathies caused by Neisseria meningitidis associated with other bacteria]. Presse Med (1993) 0.79
[HR 810 (cefpirome). Experimental evaluation of the in vitro and in vivo antibiotic activity of a new amino-2-thiazole methoxy- imino cephalosporin]. Pathol Biol (Paris) (1985) 0.79
Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice. J Antimicrob Chemother (2004) 0.79
[Interaction of roxithromycin with human polymorphonuclear neutrophils in vitro and ex vivo]. Pathol Biol (Paris) (1988) 0.79
Cefuroxime: pharmacokinetic study in bronchial secretions. Proc R Soc Med (1977) 0.79
Telithromycin--an innovative ketolide antimicrobials. Jpn J Antibiot (2001) 0.78
[Polychemotherapy of ovarian cancer via combined intravenous and intraperitoneal routes. Technic and preliminary results]. J Gynecol Obstet Biol Reprod (Paris) (1986) 0.78
Pharmacokinetics of quinolones with special reference to the respiratory tree. J Antimicrob Chemother (1993) 0.78